20 Mar, 2018
- Market News
- Analyst Reports
- Personal Finance
Juno Therapeutics Inc. (NASDAQ: JUNO) shares continued to surge on Monday after Celgene Corp. (NASDAQ: CELG) had entered into an agreement to acquire Juno for a total of $9 billion or $87 per share. Juno shares rose 27 percent during Monday&rsq..
Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..
Revance Therapeutics Inc (NASDAQ: RVNC) is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions. On Tuesday shares of the Revance jumped about 10% a after the company announced its n..
Co-Founder of Insys Therapeutics Inc. (NASDAQ: INSY) was arrested on Thursday by federal agents and charged with bribery, racketeering, and fraud to cause the illegal distribution of Fentanyl.John Kapoor was taken into custody in Phoenix, Arizona. K..
Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..
Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..
Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..
All rights reserved.